Announcement of the progress of the company's committed items at the time when the stock was listed on TWSE.

 Announcement of the progress of the company's
committed items at the time when the stock was listed
on TWSE.

1.Date of occurrence of the event:2022/07/08
2.Company name:Polaris Group
3.Relationship to the Company (please enter "head office" or
  "subsidiaries"):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
As requested by TWSE's letter No. 1111700849 issued on March 25,2022.
The Company issued the following undertakings when its stock was
initial listed:
(1)The disclosure in prospectuses for initial stock listing:
A.The company is engaged in the research and development and manufacture
of new biopharmaceutical, its main technology sources and patent
protection, as well as the research and development progress, market
competitiveness, potential risks and countermeasures of various new drugs.
B.The company has engaged in drug Contract Development and Manufacturing
Organization (CDMO) since 2019, its development plan, competitive
advantages and expected customer sources, as well as potential risks
and countermeasures.
C.The company needs a huge amount of capital for new drug research and
development and CDMO business, future capital needs and planning, and may
face the risk of working capital turnover and countermeasures.
(2)The period of the shares for centralized custody is extended to three
years.One-third of shares can be got back after each year from the start
of listing.
(3)The Article 42.1 of the Articles of Association for independent
directors to convene shareholders' meetings was deleted before listing.
6.Countermeasures:
The implementation status as of 2022/07/08 is as follows：
(1)Have been described in the Public disclosure for initial stock listing
(2)Have completed the centralized custody of shares.
(3)Have been approved at the 2022/06/02 general shareholder' meeting.
7.Any other matters that need to be specified:
 It takes considerable time and expenses to develop a new drug of which
 success can't be guaranteed. Investors shall bear such investment risk
 that warrants careful assessment before making investment decisions.